Rapid Molecular Assays for the Diagnosis of Drug-Resistant Tuberculosis [Corrigendum]

Nandlal L, Perumal R, Naidoo K. Infect Drug Resist. 2022;15:4971–4984.

Table 2 Performance of WHO-Endorsed Molecular Diagnostics for Drug-Resistant TB Diagnosis and Drug-Susceptibility Testing

The authors have advised that there is an error in Table 2 on pages 4975 and 4976. The text “$1240” in the Cost Per Test column for the TRUENAT MTB-RIF Dx (Molbio) 2020 row should read “$12.40”.

This error was introduced by the Editorial staff during the publication process. The correct Table 2 is shown below.

Read the original article

© 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.